SRC and chronic myelogenous leukemia, BCR-ABL1 positive: Therefore, the small molecule inhibitor with overlapping activity against both Abl and Src (i.e., Dasatinib) results in enhanced activity against CML compared with that of Imatinib, which is a potent Abl tyrosine kinase inhibitor but has negligible activity against Src kinases [10,36].